Alteogen Inc. has signed a licensing agreement with Cristalia Produtos Quimicos Farmaceuticos Ltda. for ALT-P1, a persistent growth hormone for children. Under the accord, Cristalia will invest about KRW 50 billion (USD 42.4 million) into conducting Phase II and III clinical trials in Brazil after producing the treatment's candidate. After the completion of the clinical trial, Cristalia will sell the product in Latin America, including Brazil, while Alteogen will receive the research data and market the product in the rest of the world. The two companies will also receive royalties from each other on the product sales in their respective region. Deal History: Announced: On April 26, 2017, Alteogen signed a letter of intent to license its long-acting drug for growth hormone deficiency to Cristalia.